Gapping up
In reaction to strong earnings/guidance:
- SMPL +9%
Other news:
- TWO +46.3% (provides update; states liquidity remains strong)
- MESO +31.2% (clears investigational new drug application for mesoblast to use remestemcel-l in patients with acute respiratory distress syndrome caused by COVID-19)
- CODX +31% (receives FDA Emergency Use Authorization for COVID-19 Test)
- RDHL +18.1% (announces first COVID-19 patient treated with opaganib in israel under compassionate use)
- TCS +13.9% (provides store operations and customer service update)
- XBIT +11.4% (announces collaboration for FDA program for US blood centers to begin collecting and distributing convalescent plasma from COVID-19 healed patients)
- LGIH +10.8% (reports March closings increased 40.5% yr/yr)
- OSUR +9.5% (receives BARDA contract for rapid oral fluid pan-SARS-coronavirus in-home self-test)
- AXSM +9.5% (reports Phase 3 trial of AXS-07 met primary endppoints)
- VRA +8.3% (announces it will continue to furlough the majority of its store employees, announces other actions)
- SEAS +8% (senior mgmt changes)
- SDC +6.4% (provides update in response to COVID-19 outbreak)
- MYGN +6.2% (receives reimbursement for the BRACAnalysis diagnostic system in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC)
- MNK +5.9% (initiates rolling submission of Biologics License Application to FDA for StrataGraft)
- LMNX +4.5% (receives Emergency Use Authorization from FDA for its ARIES SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19)
- INCY +4.4% (presents Phase 3 data from the TRuE-AD Program of Ruxolitinib Cream; plans to file NDA before end of 2020)
- MMM +4.3% (responds to reports of alleged seizure of N95 respirator shipments)
- JPM +4.2% (CEO Jamie Dimon says bank will consider suspending dividend only during "extremely adverse conditions")
Analyst comments:
- TEVA +6.5% (upgraded to Buy from Neutral at UBS)
- EBAY +5% (upgraded to Buy from Neutral at Guggenheim)
- TSLA +4.8% (upgraded to Buy from Hold at Jefferies)
- INTC +4.3% (upgraded to Mkt Perform from Underperform at Raymond James)
- CHRW +4.1% (upgraded to Overweight from Equal-Weight at Stephens)